病院薬学
Online ISSN : 2185-9477
Print ISSN : 0389-9098
ISSN-L : 0389-9098
腎機能正常患者に対する高脂血症治療薬の腎機能への影響
齊藤 誠石田 義裕吉田 弘之入江 由佳寺川 伸江岩井 章洋
著者情報
ジャーナル フリー

2000 年 26 巻 4 号 p. 443-450

詳細
抄録
Acute coronary syndrome (ACS) was recently revealed to occur when a fragile plaque in a fibrous capsule breaks off and a thrombus produced at the broken site obstructs the vascular cavity. Anti-hyperlipidemic agents have been reported to be effective in preventing this onset of ACS through its stabilizing effect on these plaques, thereby leading to its extensive application. However, no reports have yet comparatively examined the influence of two combined antihyperlipidemic agents of different species on the renal functions including blood urea nitrogen (BUN) and serum creatinine (Scr) in patients whose kidneys function normally. Therefore, BUN, total cholesterol (TC), neutral triglyceride (TG), high density lipoprotein (HDL), and low density lipoprotein (LDL) were comparatively analyzed before and one year after treatment with single pravastatin (CS), single bezafibrate (BF) or CS-F BF combination in patients first diagnosed to have hyperlipidemia at our hospital. While TC and LDL significantly decreased in the CS group, TG significantly decreased and HDL significantly increased in the BF group. In the CS-FBF combination group, TC, TG and LDL significantly decreased while HDL significantly increased. In the three groups, no significant increase was detected for BUN or Scr. As mentioned above, the administration of CS and BF to patients with normal renal functions therefore appears to be safe since no renal disturbances were observed.
著者関連情報
© 一般社団法人 日本医療薬学会
前の記事 次の記事
feedback
Top